Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | XBP1 | P17861 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347078 | 0.90 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL16040190 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL1603669 | 0.87 | SMN1; SMN2 (0.74) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL5141437 | 0.86 | KMT2A (0.65) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL7565660 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL31236338 | 0.84 | MAPT (0.77) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL5142590 | 0.84 | MAPT (0.77) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL333131 | 0.83 | ALDH1A1 (0.62) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL28709827 | 0.83 | TSHR (0.64) | SMN1; SMN2MEN1MAPTKMT2AGAA | |
| SCHEMBL2184782 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1MAPTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-1663973-B3 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| EP-1663973-B1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | disclosed |
| US-20120269872-A1 | NOVEL SALT 628 | ASTRAZENECA AB (SE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269872-A1 | NOVEL SALT 628 | ASTRAZENECA AB (SE) | 2012-10-25 | — | — | US | disclosed |
| US-8232296-B2 | Salt 628 | ASTRAZENECA AB (SE) | 2012-07-31 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
| WO-2005080372-A1 | DIHYDROPYRIDINONE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080372-A1 | DIHYDROPYRIDINONE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1562902-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005026124-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026123-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | SMN1; SMN2 4108/4885MEN1 4426/4885MAPT 4727/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885MEN1 1514/4885MAPT 3235/4885 |
| US-20120269872-A1 | NOVEL SALT 628 | REN, SCN8A, SLC38A7 | SMN1; SMN2 1703/4885MEN1 1670/4885MAPT 773/4885 |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | SMN1; SMN2 1066/4885MEN1 3423/4885MAPT 1847/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885MEN1 1514/4885MAPT 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.